Alteogen (196170.KQ)

Executive Summary

Alteogen is a South Korean biopharmaceutical company focused on developing biosimilars and innovative drug delivery technologies. With a market capitalization of approximately $19.7 billion, the company leverages proprietary platforms to improve drug formulations and delivery systems, targeting a range of therapeutic areas including oncology and ophthalmology. Alteogen's pipeline includes ALT-P7, a HER2-targeted antibody-drug conjugate for breast cancer, which completed Phase 1 trials, and ALT-L9, a biosimilar candidate to aflibercept for neovascular age-related macular degeneration, also in Phase 1. The company has six commercial products on the market, indicating a track record of successful development and commercialization.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 trial for ALT-P7 (HER2-positive breast cancer)60% success
• Q4 2026Initiation of Phase 3 trial for ALT-L9 (aflibercept biosimilar)50% success
• TBDPartnership or licensing deal for drug delivery platform40% success